The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K.
J. N. Sarkaria
Research Funding - Merck; Novartis
P. J. Peller
No relevant relationships to disclose
E. Galanis
No relevant relationships to disclose
M. S. Jacobson
No relevant relationships to disclose
W. Wu
No relevant relationships to disclose
K. A. Jaeckle
No relevant relationships to disclose
J. C. Buckner
No relevant relationships to disclose